BioCentury
ARTICLE | Clinical News

TLN-4601: Phase II start

May 19, 2008 7:00 AM UTC

This quarter, Thallion plans to start an open-label, North American Phase II trial in up to 40 patients to evaluate 480mg/m 2/day of intravenous TLN-4601 given for 2 weeks on and 1 week off in a 21-da...